Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals Q4 2024 Earnings Report

Reviva Pharmaceuticals logo
$0.97 +0.08 (+8.87%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$0.99 +0.02 (+2.06%)
As of 05/30/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Monday, March 31, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Reviva Pharmaceuticals Earnings Headlines

What is Zacks Small Cap's Forecast for RVPH Q2 Earnings?
Research Analysts Set Expectations for RVPH Q2 Earnings
Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

View Reviva Pharmaceuticals Profile

More Earnings Resources from MarketBeat